Drug Profile
MEDI 9253
Alternative Names: MEDI9253; Recombinant Newcastle disease virus encoding interleukin-12Latest Information Update: 26 Apr 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunostimulants; Programmed cell death-1 ligand-1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 06 Mar 2023 Efficacy, adverse events and Pharmacokinetics data from a phase I trial in Solid tumours presented at the 21st International Congress on Targeted Anticancer Therapies (TAT-2023)
- 28 Feb 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA, France (IV)
- 21 Feb 2023 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in France (IV) (NCT04613492)